A Message from Our CEO, Dr. Jonathan Kaufman – Expanding Our Clinical Pipeline to Target Serious and Rare Diseases

As the CEO of Lipella Pharmaceuticals, I am proud to share our progress over the past year in advancing our clinical pipeline, highlighting our commitment to addressing significant unmet medical needs and providing supportive treatments to improve the lives of cancer survivors.

We focus on areas where patients’ needs are largely unaddressed. These conditions we target include hemorrhagic cystitis, oral lichen planus, and oral Graft-versus-Host Disease (GvHD). These conditions pose severe health risks, and can significantly diminish the quality of life for those affected. Our mission is to develop safe and effective therapies for these underserved populations.

We have been granted Orphan Drug Designation by the FDA for two of our drug candidates. The first for LP-10 in the treatment of hemorrhagic cystitis, and the second for LP-410, aimed at treating oral GvHD, a serious rare disease. These designations underscore our dedication to provide effective treatment options for rare diseases.

Looking ahead, our focus remains on progressing through the clinical development phases efficiently and effectively. This focus includes our strategy to leverage existing pharmacologic mechanisms to expedite the approval process and bring our therapies to patients sooner.

We are excited by the potential of our expanded clinical pipeline, which we believe provides a strong value proposition for our investors and to potential partners. We look forward to pipeline progress and potential expansion in the near future.

Thank you to our patients, partners, and investors. Together, we are on a clear path to transforming the treatment landscape for serious and rare diseases, improving patient outcomes, and delivering value to our stakeholders.

Warm regards,
Jonathan Kaufman
CEO, Lipella Pharmaceuticals